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Abstract With the dramatic increase in the volume of
experimental results in every domain of life sciences,
assembling pertinent data and combining information from
different ﬁelds has become a challenge. Information is
dispersed over numerous specialized databases and is
presented in many different formats. Rapid access to
experiment-based information about well-characterized
proteins helps predict the function of uncharacterized pro-
teins identiﬁed by large-scale sequencing. In this context,
universal knowledgebases play essential roles in providing
access to data from complementary types of experiments
and serving as hubs with cross-references to many spe-
cialized databases. This review outlines how the value
of experimental data is optimized by combining high-
quality protein sequences with complementary experimen-
tal results, including information derived from protein
3D-structures, using as an example the UniProt know-
ledgebase (UniProtKB) and the tools and links provided on
its website (http://www.uniprot.org/). It also evokes pre-
cautions that are necessary for successful predictions and
extrapolations.
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Introduction
Combining vast amounts of data with the aim of under-
standing the complexity of living beings, e.g., in the
context of systems biology, is a central issue of modern
biology. The technological progress of the last few years
has led to a literal explosion in the quantity of available
data in life sciences, starting with the number of nucleotide
and protein sequences, but also data from proteomic and
transcriptomic studies. Likewise, the number of protein
3D-structures that are deposited at wwPDB (http://www.
wwpdb.org/) and integrated via its sites at RCSB PDB,
PDBe (formerly MSD), PDBj, and BMRB [1–4] has
increased dramatically, and ever more protein structures
are being solved. Complementary central databases and
knowledge repositories, such as the protein structure ini-
tiative structural genomics knowledgebase (PSI-SGKB) [5]
and the UniProt Knowledgebase (UniProtKB) [6, 7], play
essential roles in simplifying access to information about
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Much of the recent data are from large-scale studies, and
most new nucleotide sequences code for otherwise
uncharacterized proteins from a wide range of species,
from mammals to microbes, virus isolates, and environ-
mental samples. For the correct prediction of the function
of individual proteins and for the automated annotation of
entire genome sequences, one needs central knowledge
resources that provide information about characterized
proteins. For successful predictions, it is essential to use a
maximum of validated experimental ﬁndings from com-
plementary experiments, and to take account of the sources
of the information. The Universal Protein Resource
KnowledgeBase (UniProtKB) (http://www.uniprot.org/)
provides the scientiﬁc community with one such resource.
It gives rapid access to high-quality, reliable information,
has excellent search tools for the retrieval of speciﬁc sets of
proteins, and puts emphasis on information that is directly
derived from experimental evidence. At the same time, it
serves as a hub providing links to other databases, allowing
access to information and data which are stored in many
different formats (Fig. 1). This facilitates the interpretation
of novel experimental results and provides a solid basis for
predictions and for planning new experiments. Small
datasets can be directly downloaded from the UniProtKB
web site by following the download link on any search
result page. For downloading complete datasets, it is
recommended to use the UniProt FTP site (ftp://ftp.
uniprot.org/). UniProtKB values feedback from the scien-
tiﬁc community, with each entry displaying the appropriate
external links.
UniProtKB contains two mutually exclusive, non-
redundant sections that together give access to all the
protein sequences which are available to the public.
However, UniProtKB excludes protein sequences for most
non-germline immunoglobulins and T-cell receptors, pat-
ent application sequences, synthetic sequences, short
fragments, pseudogenes, and fusion proteins. More than
99% of the protein sequences provided by UniProtKB
come from the translations of coding sequences (CDS)
submitted to the EMBL-Bank/GenBank/DDBJ nucleotide
sequence resources. New protein sequences are integrated
in UniProtKB/TrEMBL, together with information pro-
vided by the submitting authors concerning the species and
the protein and/or gene name. Highly automated tools are
used for further annotation. Proteins are classiﬁed using
protein signatures, and assigned to families and domains.
The major protein signature databases are available
through the InterPro database [8, 9], the main tool for
characterizing and classifying UniProtKB sequences.
Depending on the entry, further information may be added
by automated annotation, using automated and manually
curated annotation rules from the UniProt RuleBase. Thus,
while users have access to high-quality automated anno-
tation and cross-references to numerous databases,
including PDB, annotation is mostly restricted to the
description of sequence-based similarity. In the same vein,
the protein name is often derived from a clone identiﬁer,
and further efforts are required to establish the identity of
the protein. When sequences differ from existing sequen-
ces, UniProtKB/TrEMBL creates separate entries for the
gene products from a given organism. For popular or
highly expressed genes, a huge number of slightly different
sequences exists for the products of each gene, e.g., due to
polymorphisms or alternative splicing events. This gives
rise to a large number of individual UniProtKB/TrEMBL
entries, making it difﬁcult to keep track of the differences
and identify the most relevant sequence.
In contrast, UniProtKB/Swiss-Prot contains manually
annotated protein sequences, where annotators add infor-
mation gathered from scientiﬁc publications and from
protein 3D-structures, and check the output from bioin-
formatics tools. When several different protein sequences
are available for the products of one gene from a given
Fig. 1 UniProtKB serves as a knowledge repository and as a central
hub that provides links to numerous other databases. New protein
sequences are integrated in UniProtKB/TrEMBL and annotated by an
automated procedure. UniProtKB/Swiss-Prot entries are manually
annotated, combining carefully checked protein sequences with
information from the scientiﬁc literature, protein 3D-structures, and
specialised databases, together with feedback from the scientiﬁc
community
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sequence is selected by annotators. Other sequences are
then merged, and differences are carefully documented,
with the result that one UniProtKB/Swiss-Prot entry rep-
resents the products of one gene for a given species.
UniProtKB/Swiss-Prot puts emphasis on showing experi-
mental evidence, and displays in-depth information. Within
this context, protein 3D-structures are highly valuable
sources of information; they give detailed information on
interactions with other macromolecules or with small
ligands, and contribute to elucidating enzyme mechanisms.
Likewise, they can provide a basis for understanding the
molecular causes of disease, elucidate the interactions
between pathogens and their hosts, and help with the tar-
geted design of new drugs and inhibitors. 3D-structures can
reveal the details of post-translational modiﬁcations, such
as disulﬁde bonds, or the covalent attachment of cofactors,
sugars, or lipids. Protein 3D-structures help to classify
proteins, assign proteins with low sequence similarity to
known families, or identify new folds. The challenge is
then to combine knowledge derived from protein structures
with high-quality information about the protein sequence
and its variants, complement it with results from other
types of experiments, such as site-directed mutagenesis and
biochemical analyses, and make the cumulated information
accessible to the scientiﬁc community. This is the goal of
UniProtKB/Swiss-Prot, a manually annotated knowledge
resource that facilitates access to data from multiple
sources, and brings together results from protein 3D-
structures and biochemical and genetic analyses, and pro-
vides cross-references to numerous other databases.
Information gathered for well-characterized proteins is
used for propagation to uncharacterized family members,
applying stringent rules. This is accomplished by highly
trained annotators; indeed, this type of work takes expert
knowledge and constant vigilance.
Focus on model organisms and pathogens
UniProtKB/Swiss-Prot prioritizes annotation of proteins
from model organisms and from important pathogens, with
particular emphasis on proteins with known 3D-structure.
Since autumn 2008, UniProtKB/Swiss-Prot entries are
available for all 20,330 human protein-coding genes;
keeping pace with the information ﬂood and continuing to
add all the relevant information to the entries is now the
next major challenge [10]. Another major priority is the
annotation of important human pathogens from all bran-
ches of life, with particular emphasis on bacteria, such as
Mycobacterium tuberculosis and Staphylococcus aureus,
and on viruses. A dedicated web portal, ViralZone
(http://www.expasy.org/viralzone/), simpliﬁes access to
information about viruses and viral proteins, and the
associated 3D-structures. For species where the entire
proteome has been annotated in UniProtKB, the complete
set of entries can be retrieved using the keyword ‘‘Com-
plete proteome’’, e.g., for Saccharomyces cerevisiae and
Schizosaccharomyces pombe, and for numerous bacteria
and archaea, such as Escherichia coli, Mycoplasma pneu-
moniae and Methanococcus jannaschii.
UniProtKB/Swiss-Prot release 57.11 (November 2009)
contains 512,994 entries, and out of these, 15,223 contain a
database link to PDB. This corresponds to 48,904 PDB
entries—the numerical discrepancy arises from the fact that
often several structures are determined for a single protein.
In addition, a single PDB entry may contain several distinct
protein chains corresponding to several UniProt entries.
Reciprocal cross-references between UniProtKB, PDB, and
PDBSum [11] facilitate access to experimental data and
further tools. In UniProtKB, adding information from
protein 3D-structures has high priority, meaning that the
majority of proteins with experimental 3D-structures are in
the manually annotated UniProtKB/Swiss-Prot section. The
keyword ‘‘3D-structure’’ can be used to retrieve all the
corresponding UniProtKB/Swiss-Prot entries, and in com-
bination with other search terms permits to recover the
entries of interest.
Even when the structure of a protein has not been
determined, 3D-structures may be available for related
proteins, serving as templates for homology-based mod-
eling. Based on the assumption that high-quality models
can be obtained for proteins with at least 30% sequence
identity, homology-based modeling is possible for about
50% of all proteins in UniProtKB/Swiss-Prot [12, 13].
Access to automatically generated 3D-models is furnished
by database cross-references to the Swiss-Model Repos-
itory (SMR) [13] and ModBase [14], while links to HSSP
[15] help to ﬁnd suitable templates. Obviously, the
quality of a model depends not only on protein similarity,
but also on human input, and thus in UniProtKB/Swiss-
Prot, a threshold of 40% sequence identity is set for
adding links to automatically generated models from
SMR.
Protein nomenclature: problems and solutions
Human beings are highly sociable and thrive on the
exchange of news and ideas. They are also adverse to
imposed rules and nomenclature systems, and yet, the use
of standardized vocabularies and nomenclatures greatly
facilitates sharing ideas and ﬁnding pertinent information.
Thus, organism-speciﬁc nomenclature systems for genes
and proteins have been created. For humans and verte-
brates, recommended gene names are based on the work of
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unique, standardized, and user-friendly gene symbols to
human genes [16]. For microbes, the use of standard gene
names and ordered locus tags is common practice, but this
is unfortunately not the case for mammalian genes and
proteins, in spite of long-standing appeals for using stan-
dardized nomenclature [17, 18]. Many authors prefer to
coin their own names for the proteins that they are working
on, even when an ofﬁcial gene name already exists, with
the consequence that it is difﬁcult to ﬁnd all the informa-
tion related to a given protein. Worse, authors sometimes
name their favorite protein using a term that is already used
to design another protein or gene, or they choose names
that make it extremely hard to ﬁnd relevant information,
e.g., the gene name ‘‘Light’’ used as synonym for mouse
Tnfsf14 (Q9QYH9). This goes without mentioning all
the proteins that are known as ‘‘p35’’, e.g., annexin A1
(P07150), sororin (Q96FF9), cyclin-dependent kinase 5
activator 1 (P61809), etc. Even people working in the ﬁeld
may miss information about their favorite protein when it is
published using an alternative name. In an era where vast
amounts of data are generated, people need rapid and
accurate information on proteins they are not familiar with,
and the use of non-standard nomenclature makes it very
difﬁcult to ﬁnd all the relevant information.
To alleviate these problems and provide access to
essential information, UniProtKB/Swiss-Prot lists not only
the recommended names for genes and proteins, but also
the synonyms that are found in the literature. It is also
possible to retrieve protein entries using PDB identiﬁers or
sequence identiﬁers, such as AY037155 (for the nucleotide
sequence), or AAK67645 (for the protein sequence).
Indeed, more and more journals insist that authors cite a
sequence identiﬁer from a public database, such as Uni-
ProtKB, EMBL-Bank [19], or GenBank [20], to indicate
unambiguously the protein and organism they used for
their experiments.
Finding relevant protein sequence information in a sea
of data
Currently, most protein sequences are deduced from the
nucleotide sequence of the corresponding gene or cDNA,
and proteins are often engineered in order to investigate a
particular phenomenon or to determine the 3D-structure of
an enzyme with bound substrate. Since the advent of
recombinant DNA technology, it is rare to study a protein,
or determine a 3D-structure, when the corresponding gene
has not been cloned. Exceptions exist, but these are mostly
directly-sequenced small proteins, e.g., snake venom neu-
rotoxin P59276. Reliable sequence information is an
essential basis for a large part of modern life sciences, and
access to high-quality protein sequence data is taken for
granted.
For eukaryotes, a single gene often gives rise to many
protein sequences, due to alternative splicing, alternative
initiation, or alternative promoter usage. Additional com-
plexity is created by polymorphisms and disease mutations.
Likewise, many similar sequences are submitted for pop-
ular microbial proteins. As a consequence, for a single
gene, many different sequences and many sequence data-
base entries may co-exist, making it difﬁcult to keep an
overview and determine what is the most relevant
sequence. Different strategies exist to deal with this prob-
lem; for example, RefSeq [21] reduces this complexity
by displaying carefully chosen reference sequences. For
alternatively spliced genes, RefSeq provides separate
entries for individual isoforms. UniProtKB/Swiss-Prot
employs an alternative strategy and groups the protein
sequences derived from a single gene from a given
organism into a single entry. Differences are clearly doc-
umented, indicating whether these are due to alternative
splicing events, polymorphisms, or possible sequencing
errors. From one UniProtKB/Swiss-Prot entry, it is possible
to create all the splice variant sequences, so that these can
be analyzed independently. This helps in interpreting
BLAST searches, and in keeping the overview in a sea of
sequence data. Grouping all the submitted sequence data,
all the commonly used names, and all the corresponding
cross-references to the PDB archive in a single entry
facilitates the rapid retrieval of complementary information
associated with a protein.
For human, several groups and consortia endeavor to
ﬁnd the most representative sequence for each protein-
coding gene, based on the genome sequence and infor-
mation about prevalent polymorphisms and isoforms, e.g.,
RefSeq and CCDS [22]. This also corresponds to the
goals of UniProtKB/Swiss-Prot regarding the protein
world, and constant efforts are being made to show both
the most relevant sequence and its variants. Database
cross-references are provided to resources dealing with
sequences and gene models, such as Ensembl [23] and
RefSeq, and sequences are constantly being reviewed in
collaboration with CCDS and Refseq. Information about
polymorphisms and human disease mutations is added
from scientiﬁc publications, and by integrating validated
polymorphisms from dbSNP [24]. For human and mouse,
the average entry contains, respectively, 6.8 and 4.3 cross-
references to EMBL, thereby ensuring the reliability of
the shown sequence, and providing information about
sequence variation due to alternative splicing events or
polymorphisms. Further information about human proteins
and defects that are linked to genetic diseases is found in
the Online Mendelian Inheritance in Man (OMIM) data-
base [25].
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When confronted with an unfamiliar protein, it is important
to have rapid access to a maximum of reliable information
about its function, the pathways it is involved in, known
interaction partners, its subcellular location, etc. This
includes information about the role of individual residues,
e.g., in binding a speciﬁc ligand or as active site residues in
catalysis. Another important angle is to identify proteins
that are still uncharacterized as targets for future research.
Finding information takes time, due to the fact that infor-
mation is dispersed in the scientiﬁc literature and in many
specialized databases. As a universal protein knowledge-
base, UniProtKB/Swiss-Prot combines carefully checked
protein sequences with detailed information from multiple
sources, including protein 3D-structures, and presents this
in a highly structured and user-friendly manner (Fig. 2).
The ‘‘general annotation’’ section indicates the function of
a protein, its subunit structure, subcellular location, possi-
ble involvement in human disease, and other such general
information. Information about the roles of individual
residues is found in the ‘‘sequence annotation’’ section,
where the use of dedicated ‘‘feature keys’’ simpliﬁes
ﬁnding speciﬁc pieces of information, e.g., about residues
that bind metal ions or that are involved in catalysis.
Dedicated ‘‘feature keys’’ are also used to indicate the
extents of cleavable signal or targeting sequences of pro-
peptides, of the mature protein chains, or of particular
domains or repeats, as illustrated by human prostate-spe-
ciﬁc antigen KLK3 (P07288). Dedicated keywords, such as
‘‘Signal’’, ‘‘Secreted’’, ‘‘Serine protease’’, and ‘‘Zymogen’’
facilitate rapid classiﬁcation and the retrieval of a set of
similar proteins. Experimental qualiﬁers are added when
speciﬁc information is propagated from a related entry or is
derived from a prediction. Thus, when the N-terminus of a
mature protein has been determined, as for KLK3
(P07288), no special comment is added. ‘‘By similarity’’
means that there is experimental evidence for a closely
related protein, while ‘‘Potential’’ indicates data derived
from the use of bioinformatics tools, e.g., for the prediction
of cleavable signal sequences or transmembrane segments,
where experimental evidence is not always available. This
distinction is important; analysis of experimentally deter-
mined signal sequences makes it possible to constantly
reﬁne and improve prediction tools.
More and more of this information is presented under
the form of controlled vocabularies and ontologies, to
simplify data retrieval and computer-parsing. When inter-
preting data and building models, it is important to use
direct experimental evidence as far as possible, to know the
origins of the information, and to have access to the ori-
ginal data. Thus, UniProtKB/Swiss-Prot entries indicate the
publications from which the information was taken, and
provide database cross-references to specialized source
databases.
Rapid identiﬁcation is essential, and key information is
already present in the lines devoted to the protein names.
This includes the ‘‘recommended name’’, the EC number
for enzymes, and commonly used ‘‘alternative names’’
found in the literature, plus abbreviations derived from the
recommended and alternative names. Likewise, keywords
and links to GO terms [26] permit a rapid classiﬁcation of
proteins, regarding their molecular function, the process
they are involved in, or in which cellular component they
reside, and can be used to retrieve particular protein sets.
While GO terms are extremely popular and easy to use, one
should not forget to distinguish terms that are inferred from
direct assay (IDA) or from a traceable author statement
(TAS) from terms that are inferred from electronic anno-
tation (IEA), e.g., based upon InterPro matches. The fact
that a protein belongs to the pectinesterase family or con-
tains a pectinesterase domain does not necessarily mean
that it has pectinase activity, as exempliﬁed by the E. coli
protein ybhC (P46130).
From primary to quaternary structure
The primary structure of a protein, i.e., its amino acid
sequence, contains all the information that is required to
determine its ﬁnal 3D-structure, and hence its biological
activity [27]. While many small proteins fold as a single
unit, the tertiary structure of larger proteins is formed by
the assembly of several structural domains, motifs, or
repeats, a striking example being the 34,350-residue-long
scaffold protein titin (Q8WZ42). Two widely used dat-
abases, CATH [28] and SCOP [29], partition proteins into
domains and classify these in a hierarchical manner. CATH
classiﬁes proteins according to class, architecture, topo-
logy, and homologous superfamily, while SCOP sorts
domains into classes, folds, superfamilies, and families.
Domains and repeats are the basic building blocks of
proteins, and the combination of several such modules
contributes to the evolution of functional diversity in pro-
teins [30]. These are catalogued in the InterPro database
[9], which integrates predictive models or ‘signatures’
representing protein domains, families, and functional sites
from multiple, diverse member databases (HAMAP [31],
Pfam [32], PROSITE [33], ProDom [34], SMART [35],
TIGRFAMs [36], PIRSF [37], SUPERFAMILY [38],
Gene3D [39], and PANTHER [40]). In all relevant
UniProtKB entries, the InterPro member databases are
cross-referenced in the ‘‘Family and domain databases’’
subsection. In addition, UniProtKB/Swiss-Prot indi-
cates the presence of particular domains or repeats in the
‘‘general annotation’’ section under the heading ‘‘sequence
From protein sequences to 3D-structures 1053similarities’’. The exact extents of such domains, repeats,
and sequence motifs are displayed in the ‘‘sequence
annotation’’ section.
In addition to the many proteins and domains that have a
characteristic native fold, many others remain essentially
unstructured in the absence of their cognate ligand [41], as
shown for the major prion protein (P04156), alpha-synuc-
lein (P37840), and islet amyloid polypeptide (P10997).
Database cross-references to DisProt help to access infor-
mation about such unstructured proteins and domains [42].
Protein interactions are key elements in signaling path-
ways, and they can directly modulate protein function and
activity. Many protein–protein interactions are identiﬁed
by small-scale studies and are published in the scientiﬁc
literature. Considering the huge number of proteins in a
living cell, many of which are still uncharacterized, the
contribution of large-scale proteomics studies is vital to
identify protein complexes and chart protein interaction
networks. Thus, several groups have studied the interac-
tome of model organisms from yeast [43, 44]t o
Caenorhabditis elegans [45] and human [46]. Interpreting
these ﬁndings and comparing results from different groups
is not easy, due to differences in design and evaluation of
the experiments, and because some studies aim to identify
Fig. 2 Extracts from the
UniProtKB/Swiss-Prot entry for
arylsulfatase A (P15289),
showing selected parts of the
General annotation, Sequence
annotation and Ontologies
section, and of one of the
summary pages that are linked
to individual ‘‘variant’’ lines.
The General annotation section
indicates the catalytic activity of
a protein, its subunit structure,
subcellular location, sequence
similarities, etc., and explains
post-translational modiﬁcations
and the involvement in human
disease. The Sequence
annotation section indicates the
roles of individual residues with
speciﬁc ‘‘feature keys’’
displaying the extents of signal
peptide and mature chain, active
site and metal-binding residues,
amino acid modiﬁcations and
natural variants. For each
variant, clicking on the amino
acid substitution leads to a
speciﬁc summary page
including, when available, data
from 3D-structure models.
Keywords and GO terms
complement the annotation
1054 U. Hinz, The UniProt Consortiumbinary interactions, while others investigate protein com-
plexes [47–49]. Novel and unexpected interactions may
represent artefacts, or may indeed shed new light on the
function of a protein. Data validation using several dif-
ferent technologies, and combination of interaction data
with studies on the subcellular location and coexpression of
putative interaction partners is essential. More and more
often, large-scale protein interaction data are deposited in a
public protein interaction database, using standardized
format and protein identiﬁers [50]. This is essential for
recovery of such information, and for comparing results
from different studies. Collaboration between interaction
databases, such as BIND [51], DIP [52], IntAct [53], and
MINT [54], aims to speed up data integration, including
data mined from the scientiﬁc literature, and to simplify
public access to these ﬁndings [50]. In UniProtKB, infor-
mation about protein interactions is gathered from the
scientiﬁc literature and shown in the ‘‘general annotation’’
section under the heading ‘‘subunit’’. There, one ﬁnds
detailed information about binary interactions between
proteins, but also about the composition of protein com-
plexes, and about factors, such as protein phosphorylation,
that modulate protein interactions. Manual evaluation
is time-consuming, and thus, in UniProtKB/Swiss-Prot,
additional information about binary protein interactions is
imported from the IntAct database, which contains both
manually annotated interactions from small-scale studies
and information derived from large-scale protein interac-
tion studies. The information is presented in the form of a
table under the heading ‘‘binary interactions’’, and links to
the IntAct annotation provide access to the experimental
details.
Ligand-binding sites and catalytic residues
A key issue for understanding the mode of action of a
protein is the identiﬁcation of physiologically relevant
ligand binding sites and catalytic residues, and here protein
3D-structures are essential. Prior knowledge and human
evaluation are then required to identify ligands that are
physiologically relevant, whether these be metal ions,
nucleotides, or various organic compounds. Common
molecules, such as phosphate, citrate, or acetate, may, or
may not, occupy the binding sites of physiological sub-
strates or inhibitors. Likewise, inorganic ions may occupy
their cognate binding sites, but in other cases the observed
ionic interactions may simply reﬂect the buffer composi-
tion. Synthetic compounds may represent transition state
analogs or substances that are of pharmaceutical interest
and occupy physiologically relevant binding sites, or they
may be irrelevant buffer components. Likewise, heavy
metals may have been included for technical reasons, but
may also occupy physiologically signiﬁcant binding sites,
as in the case of the cadmium-sensitive HTH-type tran-
scriptional regulator cmtR (P67731). In the PDB archive,
inorganic ions contribute the largest number of ligand
binding sites, with almost as many binding sites being
occupied by the large and heterogeneous class of synthetic
inhibitors and non-canonical biological molecules [55].
Dedicated tools facilitate retrieving this information from
PDB. There, scientists have access to all the data and can
extract information about the ligands they are interested in.
Public protein–ligand databases and tools, such as ReLi-
Base [56], Binding MOAD [57], and SRS 3D [58], help
ﬁnd structures with particular ligands and analysis of
protein–ligand interactions. Likewise, PDBSum provides
access to excellent tools and links. Even so, recovering
relevant information takes time. In UniProtKB/Swiss-Prot,
annotators identify physiologically relevant ligands and
display information about their binding sites in text format.
Combining these data with complementary results from
other types of experiments, e.g., mutagenesis studies,
enhances the value of these ﬁndings. Dedicated ‘‘feature
keys’’ indicate residues that interact with speciﬁc classes of
ligands, such as metal ions, nucleotides, and other small
molecules, and such ﬁne-grained annotation helps retrieval
of speciﬁc datasets. Likewise, a speciﬁc ‘‘feature key’’
indicates active site residues that are directly involved in
catalysis. There is no universally accepted deﬁnition of the
term ‘‘active site’’, and sometimes it is used in a very broad
sense, grouping residues that are directly involved in
catalysis with others that position the substrate, bind metal
cofactors, or simply line the active site pocket. In Uni-
ProtKB/Swiss-Prot, the term ‘‘active site’’ is reserved for
residues that are directly involved in catalysis, and dedi-
cated ‘‘feature keys’’ are used to indicate the roles of other
important residues, as illustrated by human arylsulfatase A
(P15289) (Fig. 2). Precise annotation rules ensure that the
same criteria are used throughout.
UniProtKB/Swiss-Prot annotation aims to show the
physiological situation, meaning that a ligand is named
‘‘ATP’’, or ‘‘substrate’’ even when a synthetic analog was
used. Frequently, several alternative names are used in the
literature for a single chemical entity, such as S-adenosyl-L-
methionine, which does not help ﬁnd all the relevant
information. Using standardized vocabulary is one way to
guarantee the retrieval of information. The use of tools that
permit searches for speciﬁc chemical structures is another
solution, and PDB implements both. UniProtKB/Swiss-
Prot aims to use a single name for every ligand, with a
preference for terms found in CHEBI [59]. Likewise, the
use of generic ligand names, e.g., ‘‘substrate’’ for enzymes,
or ‘‘carbohydrate’’ in the case of lectins, helps ﬁnd the
relevant information, and at the same time facilitates
propagation to other family members.
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While complex multicellular organisms, such as humans
or mice, can live with about 20,000 protein-coding
genes, the number of proteins is much higher, due to
alternative splicing events, but also due to post-transla-
tional modiﬁcations. Thus, the total number of human
proteins may be somewhere between 100,000 and
1,000,000 [60]. The chemical nature of post-translational
modiﬁcations is extremely diverse, ranging from proteo-
lytic cleavage to methylation, phosphorylation of speciﬁc
residues to the formation of disulﬁde bonds, and other
cross-links. This multitude of modiﬁcations results in an
equally wide spectrum of biological effects: targeting
proteins to speciﬁc cellular compartments, modulating
protein–protein interactions, or regulating protein func-
tion and turnover. For some enzymes, e.g., human
arylsulfatase A (P15289), post-translational modiﬁcation
is essential for catalytic activity (Fig. 2). Currently,
large-scale proteomics studies make a major contribution
to the identiﬁcation of protein glycosylation [61] and
phosphorylation sites, e.g., during mitosis [62]. Because
of their biological importance, UniProtKB/Swiss-Prot
prioritizes annotation of post-translational protein modi-
ﬁcations [63], using data from the scientiﬁc literature and
from protein 3D-structures.
As always, it is essential to present the information in a
user-friendly, simple, and accurate manner. General
information about post-translational modiﬁcations is shown
under the appropriate heading in the ‘‘general annotation’’
section, while the exact position and the chemical nature of
the modiﬁcations are shown in the ‘‘sequence annotation’’
section. Many of these modiﬁcations are also linked to
speciﬁc ontologies and keywords, e.g., ‘‘Glycoprotein’’ or
‘‘Phosphoprotein’’. Dedicated ‘‘feature keys’’, controlled
vocabularies, and strictly standardized annotation are
indispensable to show unambiguously the exact chemical
nature of each protein modiﬁcation and the resulting mass
change, and this is achieved in collaboration with the
RESID database [64]. This database contains a compre-
hensive collection of pre-, co- and post-translational
protein modiﬁcations and cross-links. It provides system-
atic and alternative names, formulas, and structure
diagrams, and indicates the mass changes associated with
each modiﬁcation. This in turn is required for the correct
identiﬁcation of modiﬁed peptides by mass spectrometry.
Both RESID and UniProtKB/Swiss-Prot prioritize the
annotation of proteins involved in post-translational mod-
iﬁcations. In UniProtKB/Swiss-Prot, the 480-odd classical
and up to 24 atypical protein kinases now believed to exist
in the human and mouse genome have been recently
updated and extensively annotated, providing access to up-
to-date and in-depth annotation of these proteins, plus
access to additional external resources by links from within
each entry [65].
Membrane-spanning domains: facts and predictions
Membrane proteins are essential for the manifold functions
exerted by biological membranes. They enable the ion
gradients required to drive energy metabolism, and permit
the uptake of nutrients and the export of signaling mole-
cules, waste products, and toxic compounds. Integral
membrane proteins serve as receptors that participate in
signaling cascades, and play important roles in host–path-
ogen interactions, both in invasion by pathogens and in
mediating defense responses. Membrane proteins consti-
tute about one-third of the human proteome, but they are
major targets of medical drugs, and the subject of numer-
ous pharmaceutical studies, as illustrated by the G-protein
coupled receptors (GPCRs) [66]. Thus, there is a huge
interest in elucidating the molecular mode of action of
membrane proteins. In spite of signiﬁcant progress made in
the last few years, integral membrane proteins are still
severely underrepresented in structural databases. More
often, the structures of isolated soluble domains have been
determined, as exempliﬁed by the mammalian toll-like
receptors. Still, more and more such structures are deter-
mined, e.g., the crystal structure of the E. coli rhomboid
protease glpG (P09391) [67, 68] or the solution structure of
human VDAC1 (P21796) [69]. Specialized databases, such
as the protein data bank of transmembrane proteins
(PDBTM) [70], help ﬁnd membrane proteins of known
3D-structure.
In the absence of a 3D-structure, it is technically quite
difﬁcult to determine which part of a protein is buried in a
membrane. Thus, for most proteins, putative transmem-
brane domains are predicted by bioinformatics tools. In
contrast to the situation for soluble domains, transmem-
brane domains are either all helical or all beta-strand, plus
eventual connecting loops. Numerous proteins cross the
membrane as beta-barrel structures, and protein 3D-struc-
tures have been essential for developing dedicated
prediction tools [71]. In UniProtKB/Swiss-Prot, these
proteins can be retrieved using the Keyword ‘‘Porin’’, e.g.,
E. coli maltoporin (P02943) and the mitochondrial voltage-
gated anion channel VDAC1 (P21796). Most prediction
tools have been developed to predict alpha-helical trans-
membrane domains, and they basically assume that a
hydrophobic stretch of the polypeptide chain crosses the
membrane by the shortest path, burying about 18–20 amino
acids in the membrane. This may be true for proteins with a
single transmembrane domain. For multipass membrane
proteins, helices frequently cross the membrane at a pro-
nounced angle, or are kinked, and so the path becomes
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buried in the membrane. This is illustrated by GPCRs,
the largest group of integral membrane proteins with
over 1,000 family members in human. By now, structures
for several family members have been determined,
from bovine rhodopsin (P02699) to human ADORA2A
(P29274), ADRB2 (P07550), and turkey ADRB1
(P07700). These proteins all have an extracellular N-ter-
minus, seven transmembrane helices, and a cytoplasmic
C-terminus. Several of the transmembrane helices have
distinct kinks and are tilted up to 20 with respect to the
plane of the membrane.
For other integral membrane proteins, such as human
aquaporin-1 (P29972) or Clc channel family members
(P37019), the topology is highly complex. In addition to
the expected transmembrane helices, there are short in-
membrane helices that are followed by an in-membrane
loop structure, where the protein chain enters and leaves
on the same side of the membrane without crossing the
lipid bilayer. Again, a protein 3D-structure is the pre-
requisite for determining the membrane topology, and
manual evaluation is required to arrive at a correct result.
In the same vein, for leukotriene C4 synthase (Q16873)
and the arachidonate 5-lipoxygenase-activating protein
FLAP (P20292), two proteins involved in leukotriene
biosynthesis, prediction programs consistently detect
three transmembrane helices—the experimental structures
clearly show that there are four. Moreover, prediction
tools generally fail to detect transmembrane segments that
contain polar or charged amino acid residues, and yet this
is a common phenomenon for integral membrane proteins
that are involved in active or passive transport of
hydrophilic solutes. One extreme case is represented by
the voltage-gated potassium channels, such as Q9YDF8
and P62483, where a helical segment with a basic amino
acid residue in every third position is buried in the
membrane [72, 73].
Erroneous prediction of transmembrane domains is not
restricted to transporters and pore-forming proteins, as
exempliﬁed by the caveolins (Q03135). The topology of
these proteins is known with both N-terminus and C-ter-
minus being in the cytoplasm [74]. In between is a
membrane-embedded ‘‘hairpin’’ structure that is interpreted
as a single transmembrane region by prediction programs,
leading to an erroneous prediction of the topology.
Establishing a correct prediction is further complicated
by the existence of certain proteins that on the one hand
exist as soluble, globular proteins, but on the other hand
can insert into lipid membranes, form pores and kill target
cells. Such proteins are essential constituents of the
complement membrane attack complex of cytolytic
T-cells (P07357, P02748), but are also produced by
microbes as cell-lysing toxins, e.g., Vibrio cholerae
hemolysin (P09545). Needless to say, predicting the
extent of transmembrane helices for such proteins is
extremely difﬁcult, and 3D-structures are essential to
elucidate the conformation changes involved in membrane
insertion and pore formation [75, 76]. In short, predictions
of transmembrane segments should be accepted as highly
useful tools for generating a working hypothesis, knowing
that the prediction may differ from reality in several
essential points. Some transmembrane helices will be
predicted correctly, for others the extents will differ sig-
niﬁcantly, and in other cases a transmembrane segment
will not be detected, or a hydrophobic stretch will be
erroneously predicted as transmembrane segment, mean-
ing that the predicted topology may be wrong. Taking
account of all the available experimental data is essential
to arrive at a correct result, and in this context protein
3D-structures are uniquely powerful sources of informa-
tion for establishing the correct transmembrane topology,
and the extents of the transmembrane segments. In
UniProtKB/Swiss-Prot, general information about the
subcellular location of a protein is shown in the ‘‘general
annotation’’ section, and the ‘‘sequence annotation’’ sec-
tion shows the precise details about the predicted or
experimentally validated topological domains. Manual
annotation of transmembrane domains based upon protein
3D-structures is time-consuming, but UniProtKB/Swiss-
Prot endeavors to use these data to show the correct
membrane topology.
The role of protein structures in health and disease
In spite of the low error rates associated with DNA repli-
cation, transcription, and translation, mutations occur with
a given low frequency. Large-scale alterations include the
deletion of entire genes and chromosomal cross-overs that
generate hybrid proteins, as shown for the proto-oncogene
tyrosine-protein kinase ABL1 (P00519), where defects due
to a chromosomal translocation with BCR (P11274) are a
cause of chronic and acute myeloid leukemia (CML and
AML) and of acute lymphoblastic leukemia (ALL). Protein
3D-structures show how this fusion leads to a constitutively
active kinase, and illustrate the mode of action of inhibitors
[77]. In UniProtKB/Swiss-Prot, the keyword ‘‘Chromo-
somal rearrangement’’ can be used to retrieve such
proteins. Likewise, the keyword ‘‘Proto-oncogene’’ indi-
cates proteins where mutations that alter its normal,
regulated activity or expression pattern convert the gene
product into a cancer-promoting oncogene. Such informa-
tion about disease mutations and their consequences is
displayed in the ‘‘general annotation’’ section. Cross-ref-
erences to the OMIM database provide access to further
information about such a disease.
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for another, are the most common type of mutation [78].
The consequence then obviously depends on the nature
and the position of the amino acid substitution. Neutral
polymorphisms are most often conservative substitutions
in a non-essential part of the protein. On the contrary, any
mutation that affects a catalytic residue in an essential
polypeptide, or residues essential for proper protein
folding, may cause a disease phenotype. This information
is dispersed throughout the scientiﬁc literature and spe-
cialized databases. UniProtKB/Swiss-Prot, as a universal
protein knowledgebase, aims to facilitate access to
information about polymorphisms and disease mutations.
The data are gathered from the literature, and in the case
of polymorphisms, also from dbSNP. Each variant has its
own identiﬁer and is linked to a summary page that dis-
plays the relevant information [79]. It describes the nature
of the mutation and shows it in the sequence context,
provides information about the disease that is linked to
this mutation, and lists relevant publications, and for
proteins where 3D-structures are available or modeling is
possible, it includes 3D-structure models and interactive
views of the mutated residue in its 3D environment
(Fig. 2).
Human disease can also be caused by protein misfolding
and misassembly that results in the formation of insoluble
ﬁbrils and toxic aggregates, as shown for beta-2-micro-
globulin (P61769). Natural mutations that favor formation
of amyloid ﬁbrils have been found in a number of proteins,
including the amyloid beta A4 protein (P05067), the prion
protein (P04156), transthyretin (P02766), and islet amyloid
polypeptide (P10997), and the keyword ‘‘Amyloid’’ can be
used to retrieve such proteins. 3D-structure analysis of
amyloid ﬁbrils from several proteins reveals variations of a
common, characteristic cross-beta sheet structure [80].
Such ﬁbrils can be formed by various short peptides, pro-
vided they have self-complementary sequences compatible
with the formation of a dry steric zipper. Typically, amy-
loidogenic peptides have low-complexity sequences with
residues of similar size, e.g., the sequence NNQQNY found
in yeast sup35 (P05453) [81]. Thus, the propensity towards
amyloidogenesis can be predicted [82]. Different mecha-
nisms for amyloidogenesis have been proposed, where
initially well-folded proteins would undergo structural
ﬂuctuations and partial unfolding, leading to the exposure
of hydrophobic residues, while formation of helical ele-
ments in intrinsically disordered proteins would serve as
starting point for protein interactions and the formation of
aggregates [83–85]. In the case of transthyretin (P02766),
3D-structures have shown how small ligands can stabilize
the native tetrameric conformation and prevent amyloid
formation [86], indicating the way for a possible preventive
treatment.
The relationship between protein sequence, structure
and function
The protein sequence determines the native fold of a pro-
tein, and protein structure determines the function of a
protein, be this an enzyme, a cell-surface receptor, or a
cytoplasmic scaffolding protein. Thus, it is generally
assumed that similar protein sequences give rise to similar
3D-structures, and hence to similar functions [87–89]. This
paradigm generally holds true for orthologous proteins, and
provides the basis for the annotation of uncharacterized
proteins in newly sequenced genomes. In UniProtKB/
Swiss-Prot, annotators group orthologous proteins based on
sequence similarity and alignments. Information about
function, cofactors, subcellular location, protein–protein
interactions, etc., is then gathered from the scientiﬁc lit-
erature and from protein 3D-structures. When annotating a
group of related proteins, publications and 3D-structures
for orthologous proteins from several organisms are used to
establish annotation rules and determine the limits of
propagation. This approach is used for the annotation of
proteins from all branches of life, and is the basis of
automated and manual annotation using HAMAP family
rules [31]. The use of such automated annotation tools is
essential for keeping up with the constant arrival of freshly
sequenced microbial genomes, and new microbial protein
sequences. In November 2009, the HAMAP family data-
base comprised over 1,600 manually curated protein
families, providing the basis for the annotation of over
306,000 microbial proteins in UniProtKB/Swiss-Prot.
Obviously, the higher the degree of sequence identity, the
higher is the level of conﬁdence, the determining factor
being the conservation of known key residues, such as
residues involved in catalysis or in ligand binding. Thus, it
isnotaproblemtoassignthecorrectfunctiontoorthologous
housekeeping enzymes, such as cytosolic phosphoenolpyr-
uvate carboxylase, where the residues involved in catalysis
and substrate binding are absolutely conserved, from
bacteria (Q9AEM1) and archaea (Q9UY53) to vertebrates
(P05153) and human (P35558), in spite of overall sequence
divergence.
While one can infer function with high conﬁdence when
there is only one copy of the gene for an essential protein,
much more caution is required when dealing with large
gene families, and when gene duplications have given rise
to paralogs. One gene copy may keep the ancestral function,
while other copies may evolve towards a new function, or
may accumulate deleterious mutations and become inactive
over time [87, 88, 90]. As long as the active site residues are
not mutated, the general function may be conserved, but the
substrate speciﬁcity may be somewhat different. In other
cases, family members may have lost the original activity,
in spite of high sequence similarity, and this even when the
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modifying factor family, SUMF2 (Q8NBJ7) lacks enzyme
activity and serves as regulatory subunit that modulates the
activity of SUMF1 (Q8NBK3), even though essential resi-
dues are conserved [91]. Likewise, similar structures do not
guarantee similar function. Again, one has to distinguish
orthologs from paralogs, and that is not always easy. Thus,
5-hydroxyisourate hydrolases were ﬁrst identiﬁed as trans-
thyretin-related proteins, before their enzyme activity was
established. Human transthyretin (P02766, 3bt0) and zeb-
raﬁsh 5-hydroxyisourate hydrolase (Q06S87, 2h6u) have
35% sequence identity, and their structures are at ﬁrst sight
almost identical. Both proteins are homotetramers, where
four subunits delimit a tunnel-shaped central cavity. Nev-
ertheless,this high degree of similarity is not a proof that the
proteins are orthologs and have similar functions. During
early vertebrate evolution, a duplication of the gene
encoding 5-hydroxyisourate hydrolase, an enzyme involved
in the breakdown of uric acid, gave rise to the gene for
transthyretin, a protein that transports thyroid hormone in
the blood stream. 5-hydroxyisourate hydrolase is found
from bacteria to mammals, and key residues are remarkably
conserved between prokaryotes and eukaryotes, but the
gene has been lost in the human lineage. Strikingly, the
residues that are necessary for 5-hydroxyisourate hydrolase
activity are not conserved in transthyretin [92].
So, precisely how much do you have to change a protein
before ending up with a different function? The answer is:
not at all, as exempliﬁed by the duck eye lens crystallins,
where enzymes, such as argininosuccinate lyase (P24058),
have been recruited to contribute to the optical properties of
the crystallin [93]. Gephyrin (Q9NQX3) presents another
striking example of such a ‘‘moonlighting’’ protein: it
functions as microtubule-associated protein involved in
membrane protein–cytoskeleton interactions and is thought
to anchor the inhibitory glycine receptor (GLYR) to
subsynaptic microtubules, but is also involved in molyb-
denum cofactor biosynthesis and is required for the transfer
of molybdenum to molybdopterin. These examples serve as
a reminder that protein function depends critically on the
biological context, and that predictions based on sequence
or structural similarity have their limits. In the end, even the
best prediction cannot replace experimental characteriza-
tion. Then, databases, such as UniProtKB/Swiss-Prot, have
an essential role in integrating information and promoting
access to experimental data.
The role of protein 3D-structures for functional
characterization of novel proteins
Large-scale nucleotide sequencing has led to the prediction
of numerous novel protein-coding genes, and many of
these are entirely uncharacterized, and their function is not
known. Biochemical characterization is not easy, when
nothing is known about the physiological role of a protein.
Here, protein 3D-structures can help predict a possible
function for otherwise uncharacterized proteins. One initial
goal of the structural genomics initiatives was to provide
experimental protein structures for every type of fold, so
that high-conﬁdence 3D-models could be generated for
most other proteins [12]. As a consequence, structural
genomics projects and individual scientists have targeted
proteins of biomedical interest, but also uncharacterized
microbial proteins with less than 30% sequence similarity
to already characterized proteins. This resulted in numer-
ous new 3D-structures for proteins both from mammals
and from microbial model organisms, notably E. coli,
M. tuberculosis and Bacillus subtilis, but also from archaea
and pathogenic viruses [94–98]. Since its beginnings,
structural genomics has made a large contribution to the
identiﬁcation of novel folds by determining unique struc-
tures [12, 99, 100], but during the same period, the protein
universe has considerable expanded due to large-scale
sequencing of ever more microbial genomes. This yielded a
majority of proteins that can be assigned to known fami-
lies, but also a host of unique predicted proteins with very
low sequence similarity to already known protein families.
Structural genomics provides a starting point for fur-
ther structural and functional characterization, particularly
when combined with other data. This is exempliﬁed by
the M. tuberculosis protein Rv1846c (P95163), a tran-
scription regulator of previously unknown function. Its
3D-structure showed strong similarity to S. aureus BlaI
(P0A042) and MecI (P68261), two repressors involved in
beta-lactam antibiotic resistance. In-depth functional
characterization of Rv1846c conﬁrmed its function as
transcriptional regulator for genes involved in antibiotic
resistance analogous to BlaI, and it has been renamed
accordingly [101].
Other proteins are still waiting for biochemical charac-
terization. In some cases, it is possible to predict a general
function based on the structure and the genomic context;
for example, E. coli protein ydhR (P0ACX3), a putative
monooxygenase that may play a role in the metabolism of
aromatic compounds [102]. For other proteins, the presence
of a known domain, or of a fortuitously bound ligand, such
as NAD, can suggest a general function, in the latter case
that the protein may have enzyme activity and may func-
tion as an oxido-reductase. Still, numerous small microbial
proteins present novel folds without signiﬁcant similarity
to characterized proteins, and their structures are devoid of
informative ligands. The prediction of at least an approx-
imate function for such uncharacterized proteins requires
careful manual evaluation of all the available data,
including sequence and structural similarities, genomic
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and predictions about subcellular location and post-trans-
lational modiﬁcations. Strategies, prediction tools, and
their limitations have been the subject of several excellent
publications [87, 89, 103–105]. Tools that combine several
types of queries, such as ProFunc [106], facilitate this task,
but do not eliminate the need for characterization and
human effort. Often, predictions give clues towards several
possible functions, and in depth biochemical characteriza-
tion is required to establish the precise physiological role of
such proteins. Databases, such as UniProtKB and the PSI-
SGKB, have essential roles in promoting access to existing
experimental data and helping to identify new targets.
Conclusions
The present avalanche of sequence and structural data
requires central knowledgebases with rapidly accessible,
reliable, and up-to-date information that provide a solid
base for the interpretation of new results, and a starting
point for planning further experiments. Efﬁcient harnessing
of knowledge derived from protein 3D-structures, and from
genetic and biochemical analyses, requires that these data
are easily accessible, and the value of experimental results
is optimized by the combination of complementary bio-
logical information. Exchange of data and active
collaboration between different types of databases, but also
between data producers and databases, is necessary. The
decreased cost of producing data and the technical progress
has led to an explosion in the amount of available data.
Now we need efﬁcient means for handling these data and
making them publicly accessible.
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